Related Experiment Video
Updated: Jun 25, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
Published on: June 23, 2015
Executive dysfunction in treated phenylketonuric patients
Bahare Azadi1, Arshia Seddigh, Mehdi Tehrani-Doost
1Child and Adolescent Psychiatry Dept., Institute of Psychiatry, King's College London, London, UK. bahare.azadi@iop.kcl.ac.uk
Insights
Early-treated phenylketonuria (PKU) patients with normal IQ show executive dysfunction, particularly in planning and attention. This impacts cognitive performance, highlighting the need for targeted interventions.
Area of Science:
- Neuroscience
- Pediatrics
- Genetics
Background:
- Phenylketonuria (PKU) is a genetic disorder requiring early treatment to prevent intellectual disability.
- Executive function deficits have been noted in patients with PKU, even with early and continuous treatment.
Purpose of the Study:
- To investigate executive function performance in patients with PKU diagnosed before age two and treated continuously.
- To identify specific domains of executive function affected by early-treated PKU.
Main Methods:
- A neuropsychological battery including the Tower of London (TOL), Continuous Performance Test (CPT), and Stroop test was administered.
- Ten early-treated PKU patients with normal IQ were compared to 15 typically developing controls.
Main Results:
- PKU patients performed significantly worse on the TOL task (planning) and made more omission errors on the CPT (attention).
- No significant differences were observed between groups on the Stroop test (inhibition).
- Serum phenylalanine levels did not correlate with executive function test results.
Conclusions:
- Early-treated PKU patients with normal IQ exhibit executive dysfunction, particularly in planning and attention.
- Further research is needed to compare these findings with other neurodevelopmental disorders like ADHD and autism to determine specificity to PKU.
Objectives:
Executive function deficits have been described in early and continuously treated patients with phenylketonuria (PKU). The aim of this study was to examine performance on executive function tasks of treated patients with PKU diagnosed by 2 years of age.
Patients And Methods:
Ten patients with PKU and normal intelligence score who were diagnosed before the age of 2 years and subsequently treated continuously, were compared with 15 typically developing control children on a battery of neuropsychological tests, including the tower of London (TOL), continuous performance test (CPT), and Stroop test.
Results:
PKU cases showed significantly poorer performance on the TOL task compared to the control group with the difference being significant in the first three levels of the test. With the CPT, PKU cases had significantly more omission errors than control subjects. On the Stroop test there was no statistically significant difference between the groups. No significant correlation was found between the concurrent serum phenylalanine (Phe) level and results of the executive tests in PKU patients.
Conclusion:
This study identified executive dysfunction in early-treated PKU patients with normal IQ, particularly in the planning and attention domains. Further studies are required to compare the results with those from other neurodevelopmental disorders such as ADHD and autism, to establish whether the pattern of findings is specific to PKU.
Related Concept Videos
Inborn Errors of Metabolism
Chronic Kidney Disease III: Interprofessional Care
Overview of Protein Metabolism
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Chronic Kidney Disease IV: Nursing Management
